Trial Profile
Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor-Modified pNK Cells in MUC1 Positive Advanced Refractory or Relapsed Solid Tumor
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-Cd7 CAR-NK cells (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Glioma; Liver cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors PersonGen Biomedicine
- 25 Jul 2016 New trial record